BNTX Projected Dividend Yield
ADS/BioNTech SE ( NASDAQ : BNTX )BioNTech develops immunotherapies for cancer and other diseases. Co.'s immunotherapy product candidates span the following four drug classes: messenger ribonucleic acid (mRNA) therapeutics, in which it is utilizing mRNA to deliver genetic information to cells; cell therapies, in which it is developing a range of cell therapies, including chimeric antigen receptorT cells, neoantigen-based T cell therapies and T cell receptor therapies; antibodies, in which it is developing antibodies that are designed to target immune checkpoints that modulate the patient's immune response to cancer; and small molecule immunomodulators, which is for the treatment of solid tumors in clinical testing. 12 YEAR PERFORMANCE RESULTS |
BNTX Dividend History Detail BNTX Dividend News BNTX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
2022 |
N/A |
Jun 02, 2022 |
Jun 03, 2022 |
Jun 17, 2022 |
1.5498 |
2022 Total: |
1.5498 |